Logarithmic phase cells were seeded in a 96-well plate and incubated overnight prior to addition of the designated compounds. After incubation with different concentrations of the tested compounds for 72 h, cells were incubated with MEM containing 0.5 mg/mL MTT for 2 h. The conversion of MTT to formazan by metabolically viable cells was measured by the absorbance at 570 nm in a 96-well microtiter plate reader. The percentage conversion by mock-treated control cells was used to evaluate the effect of the chemicals on cell growth and to determine the concentration that inhibited 50% of growth (GI50).
52
References
1. (a) Kim, G. H., [Extraesophageal manifestations of gastroesophageal reflux disease]. Korean J.
Gastroenterol. 2008, 52, 69; (b) Morales, M. C.; Basomba, A.; Villalmanzo, I. G.; Pelaez, A.;
Campos, A.; Guerrero, M., Crossed tolerance to pyrazolines, mephenamic acid, and glafenine in A. S. A.-triad patients desensitized to aspirin. J. Allergy Clin. Immunol. 1985, 75, 528.
2. (a) Tanitame, A.; Oyamada, Y.; Ofuji, K.; Fujimoto, M.; Suzuki, K.; Ueda, T.; Terauchi, H.;
Kawasaki, M.; Nagai, K.; Wachi, M.; Yamagishi, J., Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring. Bioorg. Med. Chem. 2004, 12, 5515;
(b) Finn, J.; Mattia, K.; Morytko, M.; Ram, S.; Yang, Y.; Wu, X.; Mak, E.; Gallant, P.; Keith, D., Discovery of a potent and selective series of pyrazole bacterial methionyl-tRNA synthetase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2231.
3. (a) Rovnyak, G. C.; Millonig, R. C.; Schwartz, J.; Shu, V., Synthesis and antiinflammatory activity of hexahydrothiopyrano[4,3-c]pyrazoles and related analogues. J. Med. Chem. 1982, 25, 1482; (b) Nagakura, M.; Ota, T.; Shimidzu, N.; Kawamura, K.; Eto, Y.; Wada, Y.,
Syntheses and antiinflammatory actions of 4,5,6,7-tetrahydroindazole-5-carboxylic acids. J.
Med. Chem. 1979, 22, 48; (c) Sugiura, S.; Ohno, S.; Ohtani, O.; Izumi, K.; Kitamikado, T.;
Asai, H.; Kato, K., Synthesis and antiinflammatory and hypnotic activity of 5-alkoxy-3-(N-substituted carbamoyl)-1-phenylpyrazoles. J. Med. Chem. 1977, 20, 80.
4. (a) Ouyang, G.; Cai, X. J.; Chen, Z.; Song, B. A.; Bhadury, P. S.; Yang, S.; Jin, L. H.; Xue, W.;
Hu, D. Y.; Zeng, S., Synthesis and antiviral activities of pyrazole derivatives containing an oxime moiety. Journal of Agricultural and Food Chemis ry 2008, 56, 10160; (b) Bandgar, B.
P.; Gawande, S. S.; Bodade, R. G.; Gawande, N. M.; Khobragade, C. N., Synthesis and
53
biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents. Bioorg. Med. Chem. 2009, 17, 8168.
5. (a) Balbi, A.; Anzaldi, M.; Maccio, C.; Aiello, C.; Mazzei, M.; Gangemi, R.; Castagnola, P.;
Miele, M.; Rosano, C.; Viale, M., Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity. European journal of medicinal chemistry 2011, 46, 5293;
(b) Neelarapu, R.; Holzle, D. L.; Velaparthi, S.; Bai, H.; Brunsteiner, M.; Blond, S. Y.;
Petukhov, P. A., Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes. J. Med. Chem. 2011, 54, 4350.
6. (a) Diana, G. D.; Carabateas, P. M.; Williams, G. L.; Pancic, F.; Steinberg, B. A., Synthesis and antiherpetic activity of some 4-[(aryloxy)alkyl]pyrazoles. J. Med. Chem. 1981, 24, 731;
(b) Gudmundsson, K. S.; Johns, B. A.; Wang, Z.; Turner, E. M.; Allen, S. H.; Freeman, G. A.;
Boyd, F. L., Jr.; Sexton, C. J.; Selleseth, D. W.; Moniri, K. R.; Creech, K. L., Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses.
Bioorg. Med. Chem. 2005, 13, 5346; (c) Moukha-chafiq, O.; Taha, M. L.; Lazrek, H. B.;
Vasseur, J. J.; De Clercq, E., Synthesis and biological evaluation of some acyclic alpha-(1H-pyrazolo-[3,4-d]pyrimidin-4-yl)thioalkylamide nucleosides. Nucleosides Nucleotides Nucleic Acids 2002, 21, 165.
7. (a) Ozdemir, Z.; Kandilci, H. B.; Gumusel, B.; Calis, U.; Bilgin, A. A., Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives.
European journal of medicinal chemistry 2007, 42, 373; (b) Kornet, M. J.; Garrett, R. J., Synthesis of 1-phenyl-2-(phenylcarbamoyl)pyrazolidines as potential anticonvulsant agents. J.
Pharm. Sci. 1979, 68, 377; (c) Kornet, M. J., Synthesis of
1-methyl-2-54
phenylcarbamoylpyrazolidines as potential anticonvulsant agents. J. Pharm. Sci. 1978, 67, 1471.
8. (a) Farghaly, A. M.; Habib, N. S.; Khalil, M. A.; el-Sayed, O. A., Synthesis of some thiazole-, 1,3,4-thiadiazole-, and 4H-1,2,4-triazole derivatives of pyrazolo[3,4-b]quinoline. Arch. Pharm.
1991, 324, 19; (b) Senga, K.; Novinson, T.; Springer, R. H.; Rao, R. P.; O'Brien, D. E.;
Robins, R. K.; Wilson, H. R., Synthesis and antitrichomonal activity of certain pyrazolo (1,5-a) pyrimidines. J. Med. Chem. 1975, 18, 312; (c) Bekhit, A. A.; Fahmy, H. T.; Rostom, S. A.;
Baraka, A. M., Design and synthesis of some substituted 1H-pyrazolyl-thiazolo[4,5-d]pyrimidines as anti-inflammatory-antimicrobial Agents. European journal of medicinal chemistry 2003, 38, 27.
9. (a) Huang, Y. R.; Katzenellenbogen, J. A., Regioselective synthesis of 1,3,5-triaryl-4-alkylpyrazoles: novel ligands for the estrogen receptor. Org Lett 2000, 2, 2833; (b) Kraus, G.
A.; Bae, J., Synthesis of N-(2-methylpropyl)-2E-undecene-8,10-diynamide, a novel constituent of Echinacea angustifolia. Tetrahedron Lett. 2003, 44, 5505.
10. Sakya, S. M.; Rast, B., Efficient synthesis of 5-alkyl amino and thioether substituted pyrazoles. Tetrahedron Lett. 2003, 44, 7629.
11. Genin, M. J.; Biles, C.; Keiser, B. J.; Poppe, S. M.; Swaney, S. M.; Tarpley, W. G.; Yagi, Y.;
Romero, D. L., Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives. J. Med. Chem. 2000, 43, 1034.
12. Dueweke, T. J.; Pushkarskaya, T.; Poppe, S. M.; Swaney, S. M.; Zhao, J. Q.; Chen, I. S.;
Stevenson, M.; Tarpley, W. G., A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers
55
increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 4713.
13. (a) Wachi, M.; Iwai, N.; Kunihisa, A.; Nagai, K., Irregular nuclear localization and anucleate cell production in Escherichia coli induced by a Ca2+ chelator, EGTA. Biochimie 1999, 81, 909; (b) Hiraga, S.; Niki, H.; Ogura, T.; Ichinose, C.; Mori, H.; Ezaki, B.; Jaffe, A., Chromosome partitioning in Escherichia coli: novel mutants producing anucleate cells. J.
Bacteriol. 1989, 171, 1496.
14. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Fujimoto, M.; Iwai, N.; Hiyama, Y.; Suzuki, K.; Ito, H.; Terauchi, H.; Kawasaki, M.; Nagai, K.; Wachi, M.; Yamagishi, J., Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
J. Med. Chem. 2004, 47, 3693.
15. (a) Gold, H. S.; Moellering, R. C., Jr., Antimicrobial-drug resistance. New Engl. J. Med.
1996, 335, 1445; (b) Payne, D. J.; Wallis, N. G.; Gentry, D. R.; Rosenberg, M., The impact
of genomics on novel antibacterial targets. Current opinion in drug discovery &
development 2000, 3, 177.
16. (a) Schimmel, P.; Tao, J.; Hill, J., Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J. 1998, 12, 1599; (b) Tao, J.; Schimmel, P., Inhibitors of aminoacyl-tRNA synthetases as novel anti-infectives. Expert opinion on investigational drugs 2000, 9, 1767.
17. Hughes, J.; Mellows, G., On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J. Antibiot. 1978, 31, 330.
18. (a) Gallant, J. E., Antiretroviral therapy in naive patients. The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
56
2000, 12 , 1, 6; (b) Yu, X. Y.; Hill, J. M.; Yu, G.; Yang, Y.; Kluge, A. F.; Keith, D.; Finn, J.;
Gallant, P.; Silverman, J.; Lim, A., A series of quinoline analogues as potent inhibitors of C.
albicans prolyl tRNA synthetase. Bioorg. Med. Chem. Lett. 2001, 11, 541.
19. (a) Blanquet, S.; Fayat, G.; Poiret, M.; Waller, J. P., The mechanism of action of methionyl-tRNA synthetase from Escherichia coli. Inhibition by adenosine and 8-aminoadenosine of the amino-acid activation reaction. Eur. J. Biochem. 1975, 51, 567; (b) Lee, J.; Kang, M. K.;
Chun, M. W.; Jo, Y. J.; Kwak, J. H.; Kim, S., Methionine analogues as inhibitors of methionyl-tRNA synthetase. Bioorg. Med. Chem. Lett. 1998, 8, 3511; (c) Jarvest, R. L.;
Berge, J. M.; Berry, V.; Boyd, H. F.; Brown, M. J.; Elder, J. S.; Forrest, A. K.; Fosberry, A.
P.; Gentry, D. R.; Hibbs, M. J.; Jaworski, D. D.; O'Hanlon, P. J.; Pope, A. J.; Rittenhouse, S.;
Sheppard, R. J.; Slater-Radosti, C.; Worby, A., Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J. Med. Chem. 2002, 45, 1959.
20. Li, Y.; Zhang, H. Q.; Liu, J.; Yang, X. P.; Liu, Z. J., Stereoselective synthesis and antifungal activities of (E)-alpha-(methoxyimino)benzeneacetate derivatives containing 1,3,5-substituted pyrazole ring. Journal of Agricultural and Food Chemistry 2006, 54, 3636.
21. (a) Prakash, O.; Kumar, R.; Sehrawat, R., Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones. European journal of medicinal chemistry 2009, 44, 1763; (b) Prakash, O.; Kumar, R.; Parkash, V., Synthesis
and antifungal activity of some new 3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl) chromones.
European journal of medicinal chemistry 2008, 43, 435.
22. Bawaskar, H. S.; Joshi, S. R., Organophosphorus poisoning in agricultural India--status in 2005. J. Assoc. Physicians India 2005, 53, 422.
57
23. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B., Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370, 737.
24. Acharya, M. R.; Sparreboom, A.; Venitz, J.; Figg, W. D., Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005, 68, 917.
25. Korner, M.; Tibes, U., Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market. Prog. Med. Chem. 2008, 46, 205.
26. Oehme, I.; Deubzer, H. E.; Wegener, D.; Pickert, D.; Linke, J. P.; Hero, B.; Kopp-Schneider, A.; Westermann, F.; Ulrich, S. M.; von Deimling, A.; Fischer, M.; Witt, O., Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer. Res. 2009, 15, 91.
27. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I., HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8.
28. Bielawski, K.; Bielawska, A.; Sosnowska, K.; Miltyk, W.; Winnicka, K.; Palka, J., Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells. Biochem. Pharmacol. 2006, 72, 320.
29. Busko-Oszczapowicz, I.; Cieslak, J., [Semisynthetic penicillins. X. Synthesis of 6-formami-dinopenicillanic acid derivatives of cyclic secondary amines]. Acta Pol. Pharm. 1973, 30, 43.
30. Marcinkowska, E.; Ziolkowski, P.; Pacholska, E.; Latos-Grazynski, L.; Chmielewski, P.;
Radzikowski, C., The new sensitizing agents for photodynamic therapy: 21-selenaporphyrin and 21-thiaporphyrin. Anticancer Res. 1997, 17, 3313.
31. Felmingham, D.; Robbins, M. J.; Ingley, K.; Mathias, I.; Bhogal, H.; Leakey, A.; Ridgway, G.
L.; Gruneberg, R. N., In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 1997, 39, 43.
58
32. Cheng, K. M.; Huang, Y. Y.; Huang, J. J.; Kaneko, K.; Kimura, M.; Takayama, H.; Juang, S.
H.; Wong, F. F., Synthesis and antiproliferative evaluation of N,N-disubstituted-N'-[1-aryl-1H-pyrazol-5-yl]-methnimidamides. Bioorg. Med. Chem. Lett. 2010, 20, 6781.
33. Pinkerton, A. B.; Huang, D.; Cube, R. V.; Hutchinson, J. H.; Struthers, M.; Ayala, J. M.;
Vicario, P. P.; Patel, S. R.; Wisniewski, T.; DeMartino, J. A.; Vernier, J. M., Diaryl substituted pyrazoles as potent CCR2 receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 807.
34. Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L., Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles. J. Org. Chem. 2004, 69, 5578.
35. Kempfer, H., How to choose a correspondence school; a guide for youth, adults, and counselors. Bellman Pub. Co.: Cambridge, Mass., 1959; p 35.
59
Addendum
N N
N NMe2 H
CHO
Figure 13 1H NMR (CDCl3, 200 MHz) spectrum of compound 2a
N N
N NMe2 H
CHO
Figure 14 13C NMR (50 MHz, CDCl3) spectrum of compound 2a
60 N
N
N NMe2 H
CHO
Figure 15 IR spectrum of compound 2a
61
N N
N NMe2 H
CHO Cl
Me
Figure 16 1H NMR (CDCl3, 200 MHz) spectrum of compound 2b
N N
N NMe2 H
CHO Cl
Me
Figure 17 13C NMR (50 MHz, CDCl3) spectrum of compound 2b
62 N
N
N NMe2 H
CHO Cl
Me
Figure 18 IR spectrum of compound 2b
63
N N
N NMe2 H
CHO Cl
Cl
Figure 19 1H NMR (CDCl3, 200 MHz) spectrum of compound 2c
N N
N NMe2 H
CHO Cl
Cl
Figure 20 13C NMR (50 MHz, CDCl3) spectrum of compound 2c
64
N N
N NMe2 H
CHO Cl
Cl
Figure 21 IR spectrum of compound 2c
65
N N
N NMe2 H
CHO Me Br
Figure 22 1H NMR (CDCl3, 200 MHz) spectrum of compound 2d
N N
N NMe2 H
CHO Me Br
Figure 23 13C NMR (50 MHz, CDCl3) spectrum of compound 2d
66
N N
N NMe2 H
CHO Me Br
Figure 24 IR spectrum of compound 2d
67
N N
N NMe2 H
CHO Cl Br
Figure 25 1H NMR (CDCl3, 200 MHz) spectrum of compound 2e
N N
N NMe2 H
CHO Cl Br
Figure 26 13C NMR (50 MHz, CDCl3) spectrum of compound 2e
68 N
N
N NMe2 H
CHO Cl Br
Figure 27 IR spectrum of compound 2e
69
N N
N NMe2 H
Figure 28 1H NMR (CDCl3, 200 MHz) spectrum of compound 3a
N N
N NMe2 H
Figure 29 13C NMR (50 MHz, CDCl3) spectrum of compound 3a
70
N N
N NMe2 H
Figure 30 IR spectrum of compound 3a
71
N N
N NMe2 H Cl
Me
Figure 31 1H NMR (CDCl3, 200 MHz) spectrum of compound 3b
N N
N NMe2 H Cl
Me
Figure 32 13C NMR (50 MHz, CDCl3) spectrum of compound 3b
72 N
N
N NMe2 H Cl
Me
Figure 33 IR spectrum of compound 3b
73
N N
N NMe2 H Cl
Cl
Figure 34 1H NMR (CDCl3, 200 MHz) spectrum of compound 3c
N N
N NMe2 H Cl
Cl
Figure 35 13C NMR (50 MHz, CDCl3) spectrum of compound 3c
74 N
N
N NMe2 H Cl
Cl
Figure 36 IR spectrum of compound 3c
75
N N
N NMe2 H
Me Br
Figure 37 1H NMR (CDCl3, 200 MHz) spectrum of compound 3d
N N
N NMe2 H
Me Br
Figure 38 13C NMR (50 MHz, CDCl3) spectrum of compound 3d
76 N
N
N NMe2 H
Me Br
Figure 39 IR spectrum of compound 3d
77
N N
N NMe2 H
Cl Br
Figure 40 1H NMR (CDCl3, 200 MHz) spectrum of compound 3e
N N
N NMe2 H
Cl Br
Figure 41 13C NMR (50 MHz, CDCl3) spectrum of compound 3e
78 N
N
N NMe2 H
Cl Br
Figure 42 IR spectrum of compound 3e
79
N N
NH2 CHO
Figure 43 1H NMR (CDCl3, 200 MHz) spectrum of compound 4a
N N
NH2 CHO
Figure 44 13C NMR (50 MHz, CDCl3) spectrum of compound 4a
80 N
N NH2
CHO
Figure 45 IR spectrum of compound 4a
81
N N
NH2 CHO
Me Cl
Figure 46 1H NMR (CDCl3, 200 MHz) spectrum of compound 4b
N N
NH2 CHO
Me Cl
Figure 47 13C NMR (50 MHz, CDCl3) spectrum of compound 4b
82 N
N NH2
CHO Me Cl
Figure 48 IR spectrum of compound 4b
83
N N
NH2 CHO
Cl Cl
Figure 49 1H NMR (CDCl3, 200 MHz) spectrum of compound 4c
N N
NH2 CHO
Cl Cl
Figure 50 13C NMR (50 MHz, CDCl3) spectrum of compound 4c
84 N
N NH2
CHO Cl Cl
Figure 51 IR spectrum of compound 4c
85
N N
NH2 CHO
Me Br
Figure 52 1H NMR (CDCl3, 200 MHz) spectrum of compound 4d
N N
NH2 CHO
Me Br
Figure 53 13C NMR (50 MHz, CDCl3) spectrum of compound 4d
86 N
N NH2
CHO
Me Br
Figure 54 IR spectrum of compound 4d
87
N N
NH2 CHO
Cl Br
Figure 55 1H NMR (CDCl3, 200 MHz) spectrum of compound 4e
N N
NH2 CHO
Cl Br
Figure 56 13C NMR (50 MHz, CDCl3) spectrum of compound 4e
88 N
N NH2
CHO
Cl Br
Figure 57 IR spectrum of compound 4e